MeDucation· @MeDucationai · X·· 3 天前评分70
正文 · 机器翻译
一路平安，@TiansterZhang！对于关注GU精选内容的人，KEYNOTE-564最终分析才是值得借鉴的那一项：长达七年的随访显示出持久的OS获益，正是这使辅助治疗pembrolizumab成为高危ccRCC公认的标准治疗。#ESMO26 #KidneyCancer
76 浏览 · 2 赞 · 0 转发 · 0 回复
会议摘要
3609P按 Renal cancer 对上
Adjuvant pembrolizumab plus belzutifan versus placebo in clear cell renal cell carcinoma: A reconstructed survival data analysis of the KEYNOTE-564 and the LITESPARK-022 trials
https://esmocongress.esmo.orgLanded in beautiful Madrid and looking forward to the GU cancer data @ESMO #ESMO26! Thanks @weoncologists & @OncoAlert for compiling top picks! See you soon @PGrivasMDPhD @montypal @DrChoueiri @AlbigesL @kalasri3 @shilpaonc & many more friends!在 X 查看被引用的帖子
来源：MeDucation · x.com